Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA PET-based Dosimetry in Upper Metastatic Gastric Cancers
NCT05214820Phase 2Active, not recruiting
- Sponsor
- Centre de recherche du CHUS
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in upper gastrointestinal cancer, sponsored by Centre de recherche du CHUS. Primary endpoint: Tumor uptake of 68Ga-PSMA at 1 hour. Started Jan 2022; status: active, not recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
upper gastrointestinal cancer
Beyond the preview
Go deeper on NCT05214820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214820.